natgillin/translations-raw huggingface dataset:
Studies in healthy subjects showed there were no major differences in the plasma exposure to cannabidiol in CYP2C19 intermediate and ultra-rapid metabolisers when compared to extensive metabolisers.
Ispitivanja na zdravim ispitanicima su pokazala kako nema većih razlika u izloženosti kanabidiolu u plazmi u CYP2C19 srednje brzom i ultra brzom metabolizatoru u usporedbi s brzim metabolizatorima.
Each ml of Epidyolex contains 79 mg of ethanol.
Jedan ml Epidyolexa sadrži 79 mg etanola.
Insufficient data are available to assess the risk of concomitant administration of other hepatotoxic medicinal products and cannabidiol (see section 4.4).
Dostupni podaci su nedovoljni za procjenu rizika od istovremene primjene drugih hepatotoksičnih lijekova i kanabidiola (vidjeti dio 4.4).
Patients with transaminase elevations greater than 3 times the upper limit of normal (ULN) and bilirubin greater than 2 times the ULN (see section 4.4).
Bolesnici s povišenjem transaminaza većim od 3 puta gornje granice normalnih vrijednosti (GGN) i bilirubinom višim od 2 puta GGN (vidjeti dio 4.4).
Suicidal behaviour and ideation have been reported in patients treated with AEDs in several indications.
Suicidalno ponašanje i suicidalne primisli su prijavljeni u bolesnika liječenih antiepilepticima u nekoliko indikacija.
- lack of energy - cold, sore throat - respiratory tract infections (pneumonia, bronchitis) - blood tests showing increases in levels of certain liver enzymes (which may be signs of liver damage) - shaking of the body or parts of it - feeling bad-tempered (irritable, aggressive) - difficulty in sleeping - cough - rash - increased appetite, weight loss - drooling - urinary tract infection - agitation - abnormal behaviour
- nedostatak energije - prehlada, bolno grlo - infekcije dišnog sustava (upala pluća, bronhitis) - krvne pretrage koje pokazuju povišenje razina određenih jetrenih enzima (što može biti znak oštećenja jetre) - drhtanje tijela ili dijelova tijela - loše raspoloženje (razdražljivost, agresivnost) - poteškoće spavanja - kašalj - osip - povećan tek, gubitak težine - slinjenje - infekcija mokraćnog sustava - uznemirenost - neuobičajeno ponašanje
In vitro data have demonstrated that cannabidiol inhibits CYP2C19, which may cause increased plasma concentrations of medicines that are metabolised by this isoenzyme such as clobazam and omeprazole.
In vitro podaci su pokazali kako kanabidiol inhibira CYP2C19, što može uzrokovati povišene plazmatske koncentracije lijekova koje ovaj izoenzim metabolizira, poput klobazama i omeprazola.
The elevations resolved after discontinuation of cannabidiol.
Povećanja su nestala nakon prekida uzimanja kanabidiola.
These adverse reactions resolved upon study completion.
Ove su nuspojave nestale do završetka ispitivanja.
The combination of cannabidiol with clobazam caused an elevation in exposure to the active metabolite N-desmethylclobazam.
Kombinacija kanabidiola i klobazama uzrokovala je povišenje izloženosti aktivnom metabolitu N-desmetilklobazamu.
No effect on cannabidiol levels.
Nema utjecaja na razine kanabidiola.
The major CYP450 isoforms responsible for the phase I metabolism of cannabidiol are CYP2C19 and CYP3A4.
Glavne izoforme CYP450 odgovorne za metabolizam kanabidiola faze I su CYP2C19 i CYP3A4.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other concurrent therapy (see sections 4.4 under hepatocellular injury and
Općenito, dozu u starijih bolesnika treba birati oprezno, obično s početkom na najnižem kraju raspona doza, pazeći na veću učestalost smanjenja jetrene, bubrežne ili srčane funkcije i pratećih bolesti ili druge istovremene terapije (vidjeti dio 4.4 pod „Hepatocelularna ozljeda“ i dio 5.2).
Cannabidiol causes dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) (see section 4.8).
Kanabidiol uzrokuje povišenje jetrenih transaminaza povezano s doziranjem (alanin aminotransferaza [ALT] i/ili aspartat aminotransferaza [AST]) (vidjeti dio 4.8).
Screw the child resistant cap back on the bottle tightly, by turning the cap clockwise - you do not need to remove the bottle adaptor, as the cap will fit over it.
Čvrsto uvijte zatvarač siguran za djecu natrag na bočicu okretanjem zatvarača u smjeru kretanja kazaljki na satu - ne morate skidati adapter bočice, jer će zatvarač ići preko njega.
If you or your patient take more Epidyolex than you should If you may have taken more Epidyolex than you should, tell a doctor or pharmacist immediately, or contact your nearest hospital casualty department, and take the medicine with you.
Ako ste uzeli više Epidyolexa nego što biste trebali, odmah recite liječniku ili ljekarniku ili se obratite najbližem odjelu za hitnu pomoć, te ponesite sa sobom lijek.
BATCH NUMBER, DONATION AND PRODUCT CODES Lot
13. BROJ SERIJE, OZNAKE DONACIJE I PROIZVODA Serija
Although exposure to cannabidiol was not notably affected by clobazam use, the levels of an active metabolite, 7-OH-CBD, were elevated by this combination.
Iako primjena klobazama nije značajno utjecala na izloženost kanabidiolu, razine aktivnog metabolita, 7-OH-CBD, su porasle u ovoj kombinaciji.
Other medicines and Epidyolex
Drugi lijekovi i Epidyolex
Cannabidiol and the metabolite 7-OH-CBD do not interact with the major renal or hepatic uptake transporters and therefore are unlikely to result in relevant drug-drug interactions: OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K, OATP1B1and OATP1B3.
Kanabidiol i metabolit 7-OH-CBD nemaju interakcija s glavnim prijenosnicima unosa u bubrege i jetru, pa stoga nije vjerojatno da će doći do relevantne interakcije među lijekovima: OAT1, OAT3, OCT1, OCT2, MATE1, MATE2K, OATP1B1 i OATP1B3.
What you or the patient need to know before taking Epidyolex.
Što Vi ili bolesnik morate znati prije nego počnete uzimati Epidyolex.
Cannabidiol can be administered to patients with mild, moderate, or severe renal impairment without dose adjustment (see section 5.2).
Kanabidiol se može primjenjivati u bolesnika s blagim, umjerenim ili teškim oštećenjem funkcije bubrega bez prilagođavanja doze (vidjeti dio 5.2).
Prior to starting treatment with cannabidiol, obtain serum transaminases (ALT and AST) and total bilirubin levels.
Prije početka liječenja kanabidiolom provjerite razine serumskih transaminaza (ALT i AST) i ukupnog bilirubina.
Concomitant use of cannabidiol and clobazam increases the incidence of somnolence and sedation compared with placebo (see sections 4.4 and 4.8).
Istovremena primjena kanabidiola i klobazama povećava incidenciju somnolencije i sedacije u usporedbi s placebom (vidjeti dijelove 4.4 i 4.8).
Subjects with moderate and severe hepatic impairment showed higher plasma concentrations of cannabidiol (approximately 2.5-5.2-fold higher AUC compared to healthy subjects with normal hepatic function).
Ispitanici s umjerenim ili teškim oštećenjem funkcije jetre su imali veće koncentracije kanabidiola u plazmi (oko 2,5-5,2-struko viši AUC u usporedbi sa zdravim ispitanicima s normalnom jetrenom funkcijom).
After multiple dosing with cannabidiol, the 7-OH-CBD metabolite (active in a preclinical model of seizure) circulates in human plasma at lower concentrations than the parent drug cannabidiol (~ 40% of CBD exposure) based on AUC.
Nakon više doza kanabidiola, metabolit 7-OH-CBD (aktivan u pretkliničkom modelu napadaja) cirkulira u ljudskoj plazmi u nižim koncentracijama nego ishodišni lijek kanabidiol (~ 40% izloženosti CBD-u) na temelju AUC-a.
79 mg anhydrous ethanol
79 mg bezvodnog etanola
Mean age of the study population was 9 years and 94% were taking 2 or more cAEDs during the trial.
Srednja vrijednost dobi populacije u ispitivanju je bila 9 godina, a 94% ispitanika je tijekom ispitivanja uzimalo 2 ili više istovremenih antiepileptika.
Mild to moderate diarrhoea and somnolence have been reported in healthy adult subjects taking a single dose of 6000 mg; this equates to a dose of over 85 mg/kg for a 70 kg adult.
Prijavljen je blaži do umjeren proljev i somnolencija kod odraslih zdravih ispitanika koji su uzeli jednu dozu od 6000 mg; to odgovara dozi od preko 85 mg/kg za odraslu osobu tjelesne težine 70 kg.
Although no formal drug-drug interaction studies have been performed for other AEDs, phenytoin and lamotrigine are addressed based on in vitro data.
Iako nisu provedena formalna ispitivanja interakcija s drugim antiepilepticima, fenitoin i lamotrigin opisani su na temelju podataka dobivenih in vitro.
In patients with LGS, population pharmacokinetic pharmacodynamic (PK/PD) modelling indicated the presence of an exposure efficacy relationship for the likelihood of achieving a ≥ 50% reduction in drop seizure frequency across the cannabidiol dose range tested (0 [placebo], 10 and 20 mg/kg/day).
U bolesnika koji imaju LGS, populacijsko farmakokinetičko/farmakodinamičko (PK/PD) modeliranje ukazalo je na postojanje odnosa djelotvornosti i izloženosti za vjerojatnost postizanja ≥ 50% smanjenja učestalosti astatskih napadaja unutar testiranog raspona doza kanabidiola (0 [placebo], 10 i 20 mg/kg/dan).
Dose adjustments of other medicinal products used in combination with cannabidiol A physician experienced in treating patients who are on concomitant antiepileptic drugs (AEDs) should evaluate the need for dose adjustments of cannabidiol or of the concomitant medicinal product(s) to manage potential drug interactions (see sections 4.4 and 4.5).
Prilagodbe doza drugih lijekova koji se primjenjuju u kombinaciji s kanabidiolom Liječnik iskusan u liječenju bolesnika koji istovremeno uzimaju antiepileptike mora procijeniti potrebu za prilagodbom doze kanabidiola ili istovremeno primjenjivanog lijeka(lijekova) kako bi pazio na potencijalne interakcije lijekova (vidjeti dijelove 4.4 i 4.5).
There are no human studies on excretion of cannabidiol in breast milk.
Nema ispitivanja na ljudima glede izlučivanja kanabidiola u mlijeko.
The phase I metabolites identified in standard in vitro assays were 7-COOH-CBD, 7-OH-CBD, and 6-OH-CBD (a minor circulating metabolite).
Metaboliti faze I identificirani u standardnim in vitro testovima su bili 7-COOH-CBD, 7-OH-CBD i 6-OH-CBD (slabije zastupljen cirkulirajući metabolit).
The lowest dose causing developmental toxicity in juvenile rats (15 mg/kg subcutaneous/100 mg/kg oral) was associated with Cmax cannabidiol exposures approximately 20 times that in paediatric subjects at 20 mg/kg/day.
Najmanja doza koja je uzrokovala razvojnu toksičnost u mladih štakora (15 mg/kg supkutano/ 100 mg/kg peroralno) je povezana s Cmax izloženostima kanabidiolu oko 20 većima od one u pedijatrijskih ispitanika pri dozi od 20 mg/kg/dan.
midazolam, phenytoin, stiripentol and valproate that are used to treat seizures - medicines used to treat acid reflux (heartburn or acid regurgitation) such as omeprazole - mitotane (a medicine used to treat tumours in the adrenal gland) - morphine or diflunisal (medicines used to treat pain) - efavirenz (a medicine used to treat HIV/AIDS) - theophylline (a medicine used to treat asthma) - caffeine (a medicine for babies who need help breathing) - propofol (an anaesthetic used for people undergoing surgery) - simvastatin, fenofibrate, gemfibrozil, (medicines used to reduce cholesterol/lipids) - enzalutamide (a medicine to treat prostate cancer) - bupropion (a medicine to help stop smoking or for treating obesity) - St. John's wort (Hypericum perforatum) (a herbal medicine used to treat mild anxiety) - medicines to treat bacterial infections, such as rifampin, clarithromycin and erythromycin
lorazepama, midazolama, fenitoina, stiripentola i valproata - lijekovi za liječenje kiselinskog refluksa (žgaravica ili vraćanje kiseline), poput omeprazola - mitotan (lijek za liječenje tumora nadbubrežne žlijezde) - morfin ili diflunisal (lijekovi protiv bolova) - efavirenz (lijek kojim se liječi HIV/AIDS) - teofilin (lijek kojim se liječi astma) - kofein (lijek za bebe kojima treba pomoć za disanje) - propofol (anestetik za osobe koje idu na operaciju) - simvastatin, fenofibrat, gemfibrozil, (lijekovi za smanjenje kolesterola/lipida) - enzalutamid (lijek za liječenje raka prostate) - bupropion (lijek za pomoć u prestanku pušenja ili za liječenje pretilosti) - gospina trava (Hypericum perforatum) (biljni lijek za liječenje blaže tjeskobe) - lijekovi za liječenje bakterijskih infekcija, poput rifampina, klaritromicina i eritromicina
Cannabidiol is extensively metabolised by the liver via CYP450 enzymes and the UGT enzymes.
Kanabidiol se ekstenzivno metabolizira u jetri putem enzima CYP450 i UGT.
Based on individual clinical response and tolerability, each dose can be further increased in weekly increments of 2.5 mg/kg administered twice daily (5 mg/kg/day) up to a maximum recommended dose of 10 mg/kg twice daily (20 mg/kg/day).
Na temelju individualnog kliničkog odgovora i podnošljivosti, svaka se doza može dodatno povećati u tjednim koracima od 2,5 mg/kg dvaput dnevno (5 mg/kg/dan) do najviše preporučene doze od 10 mg/kg dvaput dnevno (20 mg/kg/dan).
Strawberry flavour (including benzyl alcohol)
Okus jagode (uključujući benzilni alkohol)
If a patient develops clinical signs or symptoms suggestive of hepatic dysfunction, serum transaminases and total bilirubin should be promptly measured and treatment with cannabidiol should be interrupted or discontinued, as appropriate.
Ako bolesnik razvije kliničke znakove ili simptome koji sugeriraju disfunkciju jetre, treba hitno izmjeriti serumske transaminaze i ukupni bilirubin, a liječenje kanabidiolom treba privremeno ili trajno prekinuti, kako je primjereno.
The key secondary endpoint for GWPCARE1 was the proportion of patients with at least a 50% reduction in convulsive seizure frequency.
Ključna sekundarna mjera ishoda za GWPCARE1 je bio udio bolesnika sa smanjenjem učestalosti konvulzivnih napadaja od najmanje 50%.
The most frequent cause of discontinuations was transaminase elevation.
Najčešći uzrok prekida uzimanja lijeka bilo je povišenje transaminaza.
Lamotrigine
Lamotrigin
No formal drug-drug interaction studies have been conducted with cannabidiol in combination with UGT inhibitors, therefore caution should be taken when co-administering drugs that are known inhibitors of these UGTs.
Nisu provedena formalna ispitivanja interakcija među lijekovima za kanabidiol u kombinaciji s inhibitorima UGT-a, pa je potreban oprez kod istovremene primjene lijekova za koje se zna da inhibiraju UGT-ove.
Elderly patients Pharmacokinetics of cannabidiol have not been studied in patients > 55 years of age.
Stariji bolesnici Farmakokinetika kanabidiola nije proučavana u bolesnika starijih od 55 godina.
GW Pharma (International) B.V., Databankweg 26, 3821AL Amersfoort, The Netherlands e-mail: info@gwpharm.com
GW Pharma (International) B.V., Databankweg 26, 3821AL Amersfoort, Nizozemska e-pošta: info@gwpharm.com
Co-administration of cannabidiol is also predicted to cause clinically significant interactions with CYP2C8 (repaglinide) and CYP2C9 (e.g., warfarin) substrates.
Također se predviđa kako će istovremena primjena kanabidiola uzrokovati klinički značajne interakcije sa supstratima CYP2C8 (repaglinid) i CYP2C9 (npr. varfarin).
In some patients, a synergistic effect of concomitant treatment with valproate upon baseline elevated transaminases resulted in a higher risk of transaminase elevations.
U nekih je bolesnika sinergijski učinak istovremenog liječenja valproatom nakon povišene početne razine transaminaza rezultirao većim rizikom za povišenje transaminaza.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V.
Dose adjustment of any co-administered medicinal product that is known to affect the liver should be considered (e.g., valproate and clobazam) (see section 4.5).
Treba razmotriti i prilagođavanje doze svih istovremeno primijenjenih lijekova za koje je poznato da utječu na jetru (npr. valproat i klobazam) (vidjeti dio 4.5).
The pharmacokinetics of cannabidiol are complex and may cause interactions with the patient's concomitant AED treatments.
Farmakokinetika kanabidiola je složena je i može uzrokovati interakcije u bolesnika koji istovremeno uzimaju antiepileptike.
Skin and subcutaneous tissue disorders Common
Poremećaji kože i potkožnog tkiva Često
It is not known if cannabidiol is dialysable.
Nije poznato izlučuje li se kanabidiol dijalizom.
After one week, the dose should be increased to a maintenance dose of 5 mg/kg twice daily (10 mg/kg/day).
Nakon jednog tjedna dozu treba povećati na dozu održavanja od 5 mg/kg dvaput dnevno (10 mg/kg/dan).
Approximately 65% of the patients were taking concomitant clobazam.
Oko 65% bolesnika istovremeno je uzimalo klobazam.
In individual patients titration up to a maximum dose of 20 mg/kg/day may be considered, based on the benefit-risk (see Section 4.2).
Kod pojedinih bolesnika može se razmotriti titracija do maksimalne doze od 20 mg/kg/dan na temelju omjera koristi i rizika (vidjeti dio 4.2).
No human data on the effect of cannabidiol on fertility are available.
Nisu dostupni podaci o učinku kanabidiola na plodnost u ljudi.
Cannabidiol is not a substrate for or an inhibitor of the brain uptake transporters OATP1A2 and OATP2B1.
Kanabidiol nije supstrat niti inhibitor za prijenosnike unosa u mozak OATP1A2 i OATP2B1.
Placebo 20 mg/kg/day Difference or Percent Reduction Compared with Placebo (95% CI), p-valueb GWPCARE2
Placebo 20 mg/kg/dan Razlika ili postotno smanjenje u usporedbi s placebom (95% CI), p-vrijednostb GWPCARE2
Table 1: Dose adjustments in patients with moderate or severe hepatic impairment
Tablica 1: Prilagodbe doza u bolesnika s umjerenim ili teškim oštećenjem funkcije jetre
When cannabidiol and clobazam are co-administered, bi-directional PK interactions occur.
Kad se kanabidiol i klobazam primjenjuju zajedno, dolazi do dvosmjernih PK interakcija.
CYP3A4 or CYP2C19 inducers
Induktori CYP3A4 ili CYP2C19
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Epidyolex je indiciran za uporabu kao dodatna terapija napadaja povezanih sa Lennox-Gastautovim sindromom (LGS) ili Dravetovim sindromom (DS) zajedno s klobazamom u bolesnika starih 2 ili više godina.
Reduction in dose of clobazam should be considered if somnolence or sedation are experienced when clobazam is co-administered with cannabidiol.
Treba razmotriti smanjenje doze klobazama ako dođe do pojave somnolencije ili sedacije kad se klobazam primjenjuje zajedno s kanabidiolom.
The NOAEL was associated with maternal plasma exposures (AUC) approximately 50 times greater than the anticipated exposure in humans at 20 mg/kg/day.
NOAEL je povezan s izloženostima u plazmi majke (AUC) oko 50 puta većima od očekivane izloženosti u ljudi pri 20 mg/kg/dan.
Weight decreased a Grouped Terms: Pneumonia: Pneumonia, Pneumonia RSV, Pneumonia mycoplasmal, Pneumonia adenoviral, Pneumonia viral, Aspiration pneumonia; Somnolence: Somnolence, Sedation.
Smanjenje tjelesne težine a Grupni pojmovi: Upala pluća: upala pluća, upala pluća uzrokovana RSV-om, mikoplazmalna upala pluća, adenovirusna upala pluća, virusna upala pluća, aspiracijska upala pluća; Somnolencija: somnolencija, sedacija.
Dose reduction of the substrates may be necessary when cannabidiol is administered concomitantly with substrates of these UGTs.
Može biti potrebno smanjenje doze supstrata ako se kanabidiol primjenjuje zajedno sa supstratima ovih UGT-ova.
In controlled studies for LGS and DS, the incidence of ALT elevations above 3 times the ULN was 13% in cannabidiol-treated patients compared with 1% in patients on placebo.
U kontroliranim ispitivanjima za LGS i DS je primijećena incidencija povišenja ALT-a za više od 3 puta GGN od 13% u bolesnika liječenih kanabidiolom u odnosu na 1% u bolesnika na placebu.
Greater improvements in overall condition, as measured by Global Impression of Change scores at the last visit, were reported by caregivers and patients with both doses of cannabidiol (73% on
Veća poboljšanja u ukupnom stanju, mjereno rezultatima Globalnog dojma promjene na zadnjem posjetu prijavljena su i od njegovatelja i bolesnika s obje doze kanabidiola (73% na 10 mg/kg/dan,
The most commonly used cAEDs (> 25% of patients) in both trials were valproate, clobazam, lamotrigine, levetiracetam, and rufinamide.
Najčešće istovremeno primjenjivani antiepileptici (> 25% bolesnika) u oba ispitivanja su bili: valproat, klobazam, lamotrigin, levetiracetam i rufinamid.
In cannabidiol-treated patients, the incidence of ALT elevations greater than 3 times the ULN was 23% in patients taking both concomitant valproate and clobazam, 17% in patients taking concomitant valproate (without clobazam), 3% in patients taking concomitant clobazam (without valproate), and 2% in patients taking neither drug.
U bolesnika liječenih kanabidiolom je incidencija povišenja ALT-a većeg od 3 puta GGN bila 23% u bolesnika koji istovremeno uzimaju valproat i klobazam, 17% u bolesnika koji istovremeno uzimaju valproat (bez klobazama), 3% u bolesnika koji istovremeno uzimaju klobazam (bez valproata), te 2% u bolesnika koji ne uzimaju nijedan od tih lijekova.
Epidyolex is used in combination with clobazam or with clobazam and other antiepileptic medicines to treat seizures that occur with two rare conditions, called Dravet syndrome and Lennox-Gastaut syndrome.
Epidyolex se primjenjuje u kombinaciji s klobazamom ili klobazamom i drugim antiepilepticima za liječenje napadaja koji se pojavljuju u dvama rijetkim stanjima, Dravetovom sundromu i Lennox-Gastautovom sindromu.
No effects on the Cmax or AUC of cannabidiol were observed following administration of a single dose of cannabidiol 200 mg in subjects with mild, moderate, or severe renal impairment when compared to patients with normal renal function.
Nisu uočeni učinci na Cmax ili AUC kanabidiola nakon primjene jedne doze kanabidiola od 200 mg u ispitanika s blagim, umjerenim ili teškim oštećenjem funkcije bubrega u usporedbi s bolesnicima s normalnom bubrežnom funkcijom.
Adverse reactions reported with cannabidiol in placebo-controlled clinical studies are listed in the table below by System Organ Class and frequency.
Nuspojave prijavljene s kanabidiolom u kliničkim ispitivanjima kontroliranima placebom navedene su u donjoj tablici prema klasifikaciji organskih sustava i učestalosti.
As with other AEDs, a clinically relevant increase in seizure frequency may occur during treatment with cannabidiol, which may require adjustment in dose of cannabidiol and/or concomitant AEDs, or discontinuation of cannabidiol, should the benefit-risk be negative.
Kao i kod drugih antiepileptika, tijekom liječenja kanabidiolom može doći do klinički relevantnog povećanja učestalosti napadaja, što može zahtijevati prilagodbu doze kanabidiola i/ili istovremeno korištenog antiepileptika, odnosno prekid primjene kanabidiola, ako bi omjer koristi i rizika bio negativan.
Serum transaminases and total bilirubin levels should be obtained at 1 month, 3 months, and 6 months after initiation of treatment with cannabidiol, and periodically thereafter or as clinically indicated.
Razine serumskih transaminaza i ukupnog bilirubina treba izmjeriti 1 mjesec, 3 mjeseca i 6 mjeseci nakon početka liječenja kanabidiolom, te kasnije povremeno, odnosno kako je klinički indicirano.
The metabolite 7-COOH-CBD is a P-gp/MDR1 substrate and has the potential to inhibit BCRP, OATP1B3, and OAT3.
Metabolit 7-COOH-CBD je supstrat P-glikoproteina/MDR1 i ima potencijal inhibicije BCRP, OATP1B3 i OAT3.
The most common adverse reactions are somnolence, decreased appetite, diarrhoea, pyrexia, fatigue, and vomiting.
Najčešće nuspojave su somnolencija, smanjenje teka, proljev, pireksija, umor i povraćanje.
Cannabidiol can cause weight loss.
Kanabidiol može uzrokovati smanjenje tjelesne težine.